check_circleStudy Completed
Bayer Identifier:
10916
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
BAY 43 9006 in combination with doxorubicin chemotherapy in patients
Trial purpose
Primary objective: To define the safety profile of continuously administered
sorafenib in combination with 3-weekly administrations of doxorubicin in subjects with advanced, refractory solid tumors;
Secondary objectives were
• To evaluate the pharmacokinetics and pharmacodynamics of sorafenib in combination with doxorubicin and vice versa;
• To determine the objective tumor response rate including complete and partial response rates based on WHO criteria.
sorafenib in combination with 3-weekly administrations of doxorubicin in subjects with advanced, refractory solid tumors;
Secondary objectives were
• To evaluate the pharmacokinetics and pharmacodynamics of sorafenib in combination with doxorubicin and vice versa;
• To determine the objective tumor response rate including complete and partial response rates based on WHO criteria.
Key Participants Requirements
Sex
N/AAge
33 - 78 YearsTrial summary
Enrollment Goal
54Trial Dates
September 2002 - March 2008Phase
Phase 1Could I Receive a placebo
N/AProducts
Nexavar (Sorafenib, BAY43-9006)Accepts Healthy Volunteer
NoTrial design
Trial Type
InterventionalIntervention Type
N/ATrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A